CY1122823T1 - COMPOSITION COMPRISING AN ALPHA-TOCOPHEROL ESTER FOR THE PREVENTION AND TREATMENT OF ALLERGIC RHINITIS - Google Patents

COMPOSITION COMPRISING AN ALPHA-TOCOPHEROL ESTER FOR THE PREVENTION AND TREATMENT OF ALLERGIC RHINITIS

Info

Publication number
CY1122823T1
CY1122823T1 CY20201100225T CY201100225T CY1122823T1 CY 1122823 T1 CY1122823 T1 CY 1122823T1 CY 20201100225 T CY20201100225 T CY 20201100225T CY 201100225 T CY201100225 T CY 201100225T CY 1122823 T1 CY1122823 T1 CY 1122823T1
Authority
CY
Cyprus
Prior art keywords
hydrogenated
oil
alpha
prevention
caprylic
Prior art date
Application number
CY20201100225T
Other languages
Greek (el)
Inventor
Giorgio Panin
Jürgen Lamprecht
Original Assignee
Bio.Lo.Ga. S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51589387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1122823(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio.Lo.Ga. S.R.L. filed Critical Bio.Lo.Ga. S.R.L.
Publication of CY1122823T1 publication Critical patent/CY1122823T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

Σύνθεση για τοπική εφαρμογή, για χρήση στην πρόληψη και την αγωγή της αλλεργικής ρινίτιδας, που αποτελείται από έναν εστέρα άλφα-τοκοφερόλης ο οποίος επιλέγεται από την ομάδα που αποτελείται από οξική, η-προπιονική και λινελαϊκή τοκοφερόλη, και έναν ελαϊκό φορέα ο οποίος επιλέγεται από την ομάδα που αποτελείται από υδρογονωμένο πολυϊσοβουτένιο, υδρογονωμένο πολυδεκένιο και μείγματα υδρογονωμένου πολυϊσοβουτενίου ή/και υδρογονωμένου πολυδεκενίου με υδρογονωμένες πολυολεφίνες, συγκεκριμένα υδρογονωμένες C6-C14 υδρογονωμένες πολυολεφίνες, Καπρυλικό/Καπρικό Τριγλυκερίδιο, Έλαιο ΟΙus, Έλαιο Αdansonia Digitata, Σπορέλαιο Αdansonia Digitata. Κοκο-Καπoυλικό/Καπρικό, Σκουαλάνιο Ελιάς, Σκουαλένιο Ελιάς, Ηλιανθέλαιο (Heliantus Annus), Κοκο-Καπρυλικό, Ισιεννεανοϊκό Ισοεννεαΰλιο, Κυκλοπεντασιλοξάνιο, και μείγματα αυτών.Composition for topical application, for use in the prevention and treatment of allergic rhinitis, comprising an alpha-tocopherol ester selected from the group consisting of tocopherol acetate, n-propionate and tocopherol linoleate, and an oleic carrier selected from the group consisting of hydrogenated polyisobutene, hydrogenated polydecene and mixtures of hydrogenated polyisobutene and/or hydrogenated polydecene with hydrogenated polyolefins, namely hydrogenated C6-C14 hydrogenated polyolefins, Caprylic/Capric Triglyceride, OIus Oil, Adansonia Digitata Oil, Adansonia Digitata Seed Oil. Coco-Caprylic/Capric, Olive Squalane, Olive Squalene, Sunflower Oil (Heliantus Annus), Coco-Caprylic, Isoenneyl Hesienanoate, Cyclopentasiloxane, and mixtures thereof.

CY20201100225T 2014-07-22 2020-03-16 COMPOSITION COMPRISING AN ALPHA-TOCOPHEROL ESTER FOR THE PREVENTION AND TREATMENT OF ALLERGIC RHINITIS CY1122823T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141332 2014-07-22
PCT/EP2015/058368 WO2016012110A1 (en) 2014-07-22 2015-04-17 Composition comprising an ester of alpha-tocopherol for prevention and treatment of allergic rhinitis

Publications (1)

Publication Number Publication Date
CY1122823T1 true CY1122823T1 (en) 2021-05-05

Family

ID=51589387

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100225T CY1122823T1 (en) 2014-07-22 2020-03-16 COMPOSITION COMPRISING AN ALPHA-TOCOPHEROL ESTER FOR THE PREVENTION AND TREATMENT OF ALLERGIC RHINITIS

Country Status (24)

Country Link
US (1) US20170165226A1 (en)
EP (1) EP3171873B1 (en)
CN (1) CN106659709A (en)
AR (1) AR101274A1 (en)
AU (1) AU2015294663B2 (en)
BR (1) BR112017001116A8 (en)
CA (1) CA2955664C (en)
CL (1) CL2017000058A1 (en)
CO (1) CO2017000550A2 (en)
CY (1) CY1122823T1 (en)
DE (1) DE202014106007U1 (en)
DK (1) DK3171873T3 (en)
EA (1) EA201692486A1 (en)
ES (1) ES2779525T3 (en)
HR (1) HRP20200380T1 (en)
HU (1) HUE049588T2 (en)
LT (1) LT3171873T (en)
MX (1) MX369991B (en)
PE (1) PE20170437A1 (en)
PL (1) PL3171873T3 (en)
PT (1) PT3171873T (en)
RS (1) RS60103B1 (en)
SI (1) SI3171873T1 (en)
WO (1) WO2016012110A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214497A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) * 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US4269835A (en) 1979-12-13 1981-05-26 Whittle Barry J Nasal composition for relieving nasal distress
US20100055152A1 (en) * 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
DE4327089A1 (en) 1993-08-12 1995-02-16 Roshdy Ismail Composition for the treatment of allergic disorders of the airways
IT1282778B1 (en) * 1996-05-31 1998-03-31 Giorgio Panin VITAMIN "E" ACETATE AS PRODUCT FOR TOPICAL APPLICATION
ITMI981586A1 (en) * 1998-07-10 2000-01-10 Giorgio Panin VITAMIN AND ITS ESTERS FOR USE IN TOPICAL TREATMENT OF MUCOSA DISORDERS
JP2003128552A (en) 2001-08-16 2003-05-08 Rohto Pharmaceut Co Ltd Composition applicable to mucous
WO2004045556A2 (en) 2002-11-20 2004-06-03 Board Of Regents, The University Of Texas System Methods for inhibiting allergic inflammation and other responses initiated by pollens, molds, and other non-animal derived allergens
JP2008266255A (en) * 2007-04-24 2008-11-06 Project M:Kk Composition for preventing and/or treating allergic disease
US20100076072A1 (en) 2008-07-25 2010-03-25 Northwestern University Compositions and methods of vitamin e administration
IT1393056B1 (en) * 2008-09-22 2012-04-11 Bio Lo Ga Srl USE OF VITAMIN AND OR ITS DERIVATIVES FOR THE CONTROL OF ARTHROPODS
ITMI20090480A1 (en) * 2009-03-27 2010-09-28 Bio Lo Ga Srl TEXTILE SUPPORT SUCCESSFUL OF A DETERGENT / MOISTURIZING COMPOSITION
EP2723378A4 (en) * 2011-06-24 2015-01-28 Epitogenesis Inc Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators

Also Published As

Publication number Publication date
AR101274A1 (en) 2016-12-07
MX2017000906A (en) 2017-05-12
RS60103B1 (en) 2020-05-29
PL3171873T3 (en) 2020-07-13
PE20170437A1 (en) 2017-04-22
CL2017000058A1 (en) 2017-08-11
EP3171873A1 (en) 2017-05-31
CO2017000550A2 (en) 2017-03-31
EP3171873B1 (en) 2019-12-25
AU2015294663A1 (en) 2017-01-19
CN106659709A (en) 2017-05-10
US20170165226A1 (en) 2017-06-15
EA201692486A1 (en) 2017-07-31
LT3171873T (en) 2020-04-10
DK3171873T3 (en) 2020-03-16
WO2016012110A1 (en) 2016-01-28
CA2955664C (en) 2022-09-06
SI3171873T1 (en) 2020-07-31
CA2955664A1 (en) 2016-01-28
PT3171873T (en) 2020-02-25
BR112017001116A8 (en) 2022-07-05
HUE049588T2 (en) 2020-10-28
AU2015294663B2 (en) 2019-11-21
MX369991B (en) 2019-11-27
ES2779525T3 (en) 2020-08-18
HRP20200380T1 (en) 2020-08-07
DE202014106007U1 (en) 2015-07-23
BR112017001116A2 (en) 2018-01-23

Similar Documents

Publication Publication Date Title
CY1125058T1 (en) VALVENAZINE DOSAGE FOR THE TREATMENT OF HYPERACTIVITY MOVEMENT DISORDERS
CO2018008761A2 (en) Maitansinoid derivatives, conjugates of the same methods of use
CL2017000240A1 (en) Active compounds towards bromodominiums
CL2016002027A1 (en) Cyclopropylamine as an inhibitor of lsd1
CY1123354T1 (en) TOPICAL COMPOSITIONS COMPRISING A CORTICOSTEROID AND A RETINOID FOR THE TREATMENT OF PSORIASIS
CL2015002658A1 (en) Derivatives of 2,3-disubstitute 1- acyl-4-amino-1,2,3,4-tetrahydroquiniline and its use as bromodomain inhibitors
BR112016006319A2 (en) irak inhibitors and uses thereof
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
SV2017005419A (en) TRIAZOLOPIRAZINONAS AS PDE1 INHIBITORS
CL2019001339A1 (en) Inhibitors of magl.
MX2016004604A (en) Combinations of histone deactylase inhibitors and immunomodulatory drugs.
CL2019001335A1 (en) Magl inhibitors.
CL2019001336A1 (en) Inhibitors of magl.
CR20160308A (en) COMBINATIONS OF INHIBITORS OF HISTONA DEACETILASE AND IMMUNOMODULATING PHARMACOS
CL2018001171A1 (en) Imidazo [4,5-c] quinolin-2-one compounds and their use in cancer treatment
BR112015023760A2 (en) therapeutic compounds and compositions
BR112016020044A8 (en) device for contraction and expansion of implantable medical device
CL2019003398A1 (en) Pyrazole magl inhibitors.
ECSP16008797A (en) DERIVATIVES OF HETEROBICICLOARIL AS RORC2 INHIBITORS AND METHODS OF USE OF THE SAME
CL2015002180A1 (en) Combination therapy for the treatment of nosocomial pneumonia
CL2015000608A1 (en) Daptomycin formulations and uses thereof
CL2017000587A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
CY1121403T1 (en) FORMATION FOR PERSONAL HYGIENE
CO2019009932A2 (en) Dual inhibitors of magl and faah
CL2016001104A1 (en) Pharmaceutical preparation and method of its production and use.